115 related articles for article (PubMed ID: 16595916)
1. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.
Honda M; Ogura Y; Toyoda W; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
[TBL] [Abstract][Full Text] [Related]
3. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese.
Honda M; Toyoda W; Shimizu T; Horiuchi I; Kayano Y; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Drug Metab Pharmacokinet; 2007 Oct; 22(5):382-6. PubMed ID: 17965522
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
9. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
J Pharm Pharm Sci; 2006; 9(1):101-12. PubMed ID: 16849011
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
Neugebauer G; Akpan W; Kaufmann B; Reiff K
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
12. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL
J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
[TBL] [Abstract][Full Text] [Related]
13. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction.
Neugebauer G; Gabor M; Reiff K
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S142-6. PubMed ID: 1378143
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Graff DW; Williamson KM; Pieper JA; Carson SW; Adams KF; Cascio WE; Patterson JH
J Clin Pharmacol; 2001 Jan; 41(1):97-106. PubMed ID: 11225566
[TBL] [Abstract][Full Text] [Related]
16. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
17. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
[TBL] [Abstract][Full Text] [Related]
19. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective disposition of carvedilol is determined by CYP2D6.
Zhou HH; Wood AJ
Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
